الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
The study was designed to elucidate the renoprotective effect of PPAR-γ, rosiglitazone, as well as PPAR-α, flaxseed, either alone or in combination in type II induced diabetes during renal I/R. The study comprised 60 rats and type II DM was induced by a single dose of STZ injection. Animals were divided into 6 groups (n=10, each) according to the treatment protocol. Group 1: Normal rats treated with saline, normal control (NC), Group 2: Diabetic rats treated with saline, diabetic control (DC), Group 3: Diabetic renal ischemic rats treated with saline, diabetic renal ischemic control (DRIC), Group 4: Diabetic renal ischemic rats treated with rosiglitazone, 3 mg/kg/day for 1 month (Ros), Group 5: Diabetic renal ischemic rats treated with flaxseed, 20% of diet/day for 1 month (Flax), Group 6: Diabetic renal ischemic rats treated with a combination of rosiglitazone and flaxseed, in the same dose mentioned before (Ros + Flax). from our study we concluded that the pretreatment of PPAR-γ agonist rosiglitazone and PPAR-α agonist flaxseed exhibits a renoprotective effects against DN and renal I/R by improving glycemic control, inhibition of proinflammatory cytokines and modulation of apoptosis.